Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

In this study, application of Revgrey® hair serum was found to be safe and may offer some benefit in treating premature greying of hair, with slightly to moderately increased hair recovery observed in a small group of patients after 12 weeks.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

This study found that AGA patients had higher serum and epidermal irisin levels, which were associated with metabolic syndrome, dyslipidemia, and abnormal carotid intima media thickness, suggesting potential irisin resistance affecting cardiometabolic health.

This study found that the guided SEFFI technique for facial volume restoration and anti-aging is minimally invasive with a low complication rate, suggesting it as a promising treatment option.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This study suggests that the anchorage of the arrector pili muscle to the extracellular matrix is likely mediated by α5β1 integrin, with α1β1 integrin involved in muscle cell-cell adhesion.

In this case study, a 25-year-old female with premature hair graying achieved over 90% conversion of gray hair to black hair after 5 months of treatment with a topical peptide solution and hair supplements.

AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.

This study found that fractional infrared technology may improve skin laxity and thickness in the cervical area without side effects in a small group of patients.

The researchers presented a case study on Exo.Reset®, a cosmetic formulation using extracellular vesicle technology, demonstrating systematic application of recognized standards to ensure scientific rigor and regulatory compliance in skin rejuvenation product development, providing a practical model for EV-based cosmetic innovations.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

This study found that a composition including Serenoa repens extract and anti-inflammatory agents effectively suppressed inflammation-related gene expression in a keratinocyte model, suggesting a potential dual strategy for treating androgenetic alopecia.

Retinoic acid causes gland formation instead of hair in mouse skin by altering epidermal and dermal interactions.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.

In this study, the combination of low level light therapy with arginine, arterial extract, or biotin tripeptide-1 was associated with improvements in hair density and follicle structure in androgenic alopecia.

In this study, topical eflornithine reduced hair regrowth in hirsute patients following intense pulsed light therapy, suggesting it may maintain IPL-induced hair reduction over six months.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.